Market Newsdesk

For dissemination in Canada and over Canadian news services only

TORONTO, Oct. 02, 2026 (GLOBE NEWSWIRE) — Arias Resource Capital Fund IV L.P. (“ARCF IV”) announced that it has agreed to invest US$1,299,999.68 (the “Investment”) in units (“Units”) of Largo Inc. (“Largo” or the “Issuer”) (TSX: LGO) (NASDAQ: LGO). This transaction is part of Largo’s previously announced US$5.7 million registered direct offering (the “Offering”).

ARCF IV agreed to purchase 2,321,428 Units of Largo at a price of US$0.56 per Unit. Each Unit consists of one common share (“Common Share”) in the capital of Largo and one common Share purchase warrant (“Warrant”). Each Warrant has an exercise price of US$0.70 per Warrant. The Warrants are exercisable for a period of five years from the date of issuance. The securities were issued directly from treasury and the transaction closed on September 29, 2026.

Following the transaction, Arias Resource Capital Fund II L.P. (“ARCF II”), Arias Resource Capital Fund II (Mexico) L.P. (“ARCF II Mexico”), Arias Resource Capital Fund III L.P. (“ARCF III”), and Arias Resource Capital Fund IV L.P. (“ARCF IV”, and together with ARCF II, ARCF II Mexico, and ARCF III, the “ARC Funds”) will own, in the aggregate, 35,278,481 Common Shares and 7,239,461 Warrants. J. Alberto Arias has been granted, for service on the Largo Board of Directors, a total of 164,565 vested options to acquire Common Shares (“Options”), holds 336,913 Restricted Share Units (“RSUs”), and holds 62,533 Common shares directly. Additionally, Arias Resources Capital GP Ltd. (“ARC GP”) owns 6,547 shares.

Giving effect of the Offering and assuming the full exercise of the new and existing Warrants, Options, and RSUs, the Common shares held by the ARC Funds, ARC GP, and J. Alberto Arias, collectively, would total 43,019,420 Common Shares representing approximately 35.01% of the total outstanding Common Shares of Largo on a partially diluted basis. On a non-diluted basis, the ARC Group’s holdings represent approximately 30.64%. This represents a post-transaction ownership summary as outlined below:

		Common Shares issuable on exercise or conversion
	Common Shares Owned	Warrants Held	Option Shares	Restricted Share Units (“RSUs”)		Partially Diluted Total		% Share (Non- Diluted)
ARCF II	26,468,209	—	—	—		26,468,209		22.99%
ARCF III	4,918,033	4,918,033	—	—		9,836,066		4.27%
ARCF IV	2,321,428	2,321,428	—	—		4,642,856		2.02%
ARCF II (Mexico)	1,501,731	—	—	—		1,501,731		1.30%
J. Alberto Arias	62,533	—	164,565	336,913		564,011		0.05%
Arias Resource Capital GP Ltd.	6,547	—	—	—		6,547		0.01%
TOTAL:	35,278,481	7,239,461	164,565	336,913		43,019,420		30.64%

The ARC Funds are managed by Arias Resource Capital Management L.P. (the “Manager”). The respective general partner of each of the ARC Funds retains the power to make investment and voting decisions in respect of the Largo securities beneficially owned by the ARC Funds. J. Alberto Arias is the director of each of the general partners of the ARC Funds and indirectly controls the Manager. As such, Mr. Arias may be deemed to share voting and dispositive power with respect to the Largo securities beneficially owned by the ARC Funds, but he disclaims any beneficial ownership of any such securities, except to the extent of his pecuniary interest therein.

The ARC Funds may, from time to time, acquire additional securities of Largo and/or dispose of such securities as they may deem appropriate. The ARC Funds currently have no other immediate plans or intentions to acquire or dispose of securities of Largo, but depending on market conditions, general economic and industry conditions, trading prices of securities of Largo, Largo’s business, financial condition and prospects and/or other relevant factors, the ARC Funds may develop such plans or intentions in the future.

This news release has been disseminated in accordance with the early warning requirements of Canadian provincial securities laws.

For further information, please contact:

J. Alberto Arias, Director
Phone: (305) 913-5400
Email: [email protected].

The dissemination of this release in the United States or to any United States news service may constitute a violation of U.S. securities laws.

SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) — iRhythm Holdings, Inc. (NASDAQ:IRTC) today provided an update regarding the cybersecurity incident previously disclosed in June 2026. Following completion of the forensic investigation and subsequent review to determine the nature of the impacted data, the company has begun notifying impacted individuals.

As previously disclosed, on or around June 8, 2026, iRhythm detected unauthorized access in certain third-party-hosted business applications. Upon detecting the unauthorized access, iRhythm promptly implemented its incident response plan. As part of the investigation, iRhythm has been working very closely with external cybersecurity professionals experienced in handling these types of incidents. After completing the forensic investigation, iRhythm learned certain data it stores was accessed and downloaded by unauthorized individuals between June 3 and June 8, 2026.

Following the forensic investigation, iRhythm carried out a review to determine the nature of the impacted data. This review concluded the impacted data includes: patient name; patient contact information, including address, email address, and phone number; iRhythm patient account number; iRhythm device serial number; patient insurance number; date of service; and date of birth.

iRhythm has no evidence that any personal information has been or will be used to commit identity theft. However, beginning October 2, 2026, iRhythm began notifying impacted individuals for whom it maintains contact information. Notified individuals have been provided with instructions on best practices to protect their information.

Out of an abundance of caution, those served by iRhythm are encouraged to take steps to protect themselves. This includes protecting themselves against medical identity theft and identity fraud, placing a fraud alert/security freeze on their credit files, obtaining free credit reports, and remaining vigilant in reviewing financial account statements and credit reports for fraudulent or irregular activity on a regular basis.

iRhythm has also established a call center to address questions from impacted individuals. Representatives are available from 8:00 a.m. to 8:00 p.m. Eastern time, Monday through Friday, excluding major U.S. holidays, at 1-844-770-7175.

As iRhythm previously reported, the company has not identified any impact to our products, our clinical or medical device systems, our connections to customers, our manufacturing and distribution operations, patient safety, or our ability to meet patient needs. In addition, iRhythm does not store or retain individual financial account information or payment card information. The company continues to believe, as previously stated in the Current Report on Form 8-K dated June 15, 2026, that the incident is not reasonably likely to have a material impact on the Company’s financial condition or results of operations.

iRhythm is committed to maintaining the privacy and security of personal information in its possession and has taken precautions to safeguard it. iRhythm regularly evaluates and modifies its practices and internal controls to safeguard the security and privacy of the information it maintains and is taking steps to mitigate the risk to individuals impacted by this incident.

Individuals may visit iRhythm’s website https://www.irhythmtech.com/us/en/who-we-are/news-events/notice-of-data-event to learn more about the incident and steps they can take to protect their information.

About iRhythm Holdings

iRhythm is a leading digital health care company with a mission to boldly innovate to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

iRhythm Contacts

Investors	Media
Francis Pruell	Kassandra Perry
[email protected]	[email protected]

TAMPA, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a company building regulated financial infrastructure for smaller institutions, fintechs and advisors, today announced that its Compensation Committee and Board of Directors approved long-term stock option awards for members of the Company’s executive leadership team and Board of Directors.

The awards granted to the Company’s Board of Directors consist of stock options to purchase 626,881 shares of the Company’s common stock each, granted on October 1, 2026 under the AtlasClear Holdings, Inc. 2024 Equity Incentive Plan, as amended, which was previously approved by the Company’s shareholders, at an exercise price of $0.2010 per share, equal to the fair market value of the common stock based on its closing price on the NYSE American on October 1, 2026, the grant date. The options vest in equal annual installments over three years, subject to continued service. The grants also include options to purchase 150,451 shares awarded to directors for service on the board of the Company’s wholly owned subsidiary AtlasClearing, Inc. (155,451 for the Chairman of the AtlasClearing board).

“Scaling a correspondent clearing platform is work measured in years rather than quarters, and stock options help align the people doing that work with our shareholders’ long-term interests,” said Craig Ridenhour, President of AtlasClear Holdings. “The three-year vesting period is designed to retain key leaders, while the opportunity to benefit from future stock price appreciation provides an incentive to execute our strategy and build long-term shareholder value.”

The stock option awards were approved by the Compensation Committee of the Company’s Board of Directors. The Company views stock options as an important part of its strategy to attract, retain and motivate experienced executives and directors as AtlasClear continues to develop and expand its financial services platform. Because the options are priced at the market on the grant date, recipients benefit only if the stock price rises.

About AtlasClear Holdings, Inc.

AtlasClear Holdings, Inc. (NYSE American: ATCH) is building a technology-enabled financial services platform designed for trading, clearing, settlement, and banking for emerging financial institutions and fintechs. Through its wholly owned subsidiary AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.), a full-service correspondent broker-dealer registered with the SEC and FINRA, and its planned acquisition of Commercial Bancorp of Wyoming, AtlasClear seeks to deliver a vertically integrated suite of brokerage, clearing, risk management, regulatory, and commercial banking solutions. For more information, follow us on LinkedIn or X and visit www.atlasclear.com.

To stay up to date on AtlasClear’s platform strategy and market perspective, subscribe to the Company’s YouTube channel and watch the Clearing the View by AtlasClear video series.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect AtlasClear Holdings’ current views with respect to, among other things, its future operations and financial performance. Forward-looking statements in this communication may be identified by the use of words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions.

Forward-looking statements include, but are not limited to, statements regarding the expected retention, incentive and shareholder-alignment benefits of the stock option awards and expected future growth.

These statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond the Company’s control, and actual results may differ materially from those anticipated. Factors that could cause actual results to differ include, but are not limited to: the Company’s failure to enter into definitive agreements with the digital asset business or the Dawson James parties, or its failure to complete the proposed acquisitions on favorable terms or at all; failure to receive the required regulatory approvals for the proposed acquisitions, including the acquisition of Commercial Bancorp of Wyoming; the Company’s inability to integrate, and to realize the benefits of, the proposed acquisitions; delays in onboarding correspondent broker-dealers or the failure of correspondent relationships to generate the anticipated revenue; changes in general economic or political conditions; changes in the markets that AtlasClear targets; slowdowns in securities or digital asset trading or shifting demand for trading, clearing and settling financial products; and any change in laws applicable to AtlasClear or any regulatory or judicial interpretation thereof. For additional information regarding risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2026. AtlasClear undertakes no obligation to update or revise forward-looking statements, except as required by law.

Company Contact:

AtlasClear Holdings, Inc.
Email: [email protected]

Investor Relations Contact:

Jeff Ramson, CEO
PCG Advisory, Inc.
Email: [email protected]

NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) — National Healthcare Properties, Inc. (Nasdaq: NHP) (the “Company”) announced today that, as previously disclosed, all outstanding shares of its Class A common stock, $0.01 par value per share (“Class A common stock”), will automatically convert into its common stock, $0.01 par value per share (“common stock”), on a one-for-one basis. All shares of common stock will begin trading on the Nasdaq Global Market, effective at 9:30 a.m. Eastern time on October 19, 2026. The conversion will have no effect on the economic rights of holders of shares of Class A common stock and the Company’s operations.

The conversion will occur automatically and without any action on the part of shareholders pursuant to the Company’s charter documents, as amended or supplemented, as described in the Company’s Registration Statement on Form S-11 filed with the United States Securities and Exchange Commission (File No. 333-294895) in connection with the Company’s public offering of the Class A common stock. The common stock has the same preferences, rights, voting powers (one vote per share), restrictions, limitations as to dividends and other distributions, qualifications and terms and conditions of redemption or otherwise, as the Class A common stock. Following the conversion of the Class A common stock, all provisions of the Company’s charter documents, as amended or supplemented, applicable to the shares of common stock shall apply to the shares of the common stock converted from the Class A common stock. Cash will be paid in lieu of any fractional shares of Class A common stock.

Immediately upon and concurrent with such conversion, no shares of Class A common stock will remain issued or outstanding. The Company’s common stock will have a new CUSIP of 42226B600.

About National Healthcare Properties

National Healthcare Properties, Inc. (Nasdaq: NHP) is a self-managed real estate investment trust focused on acquiring, owning and investing in a diversified portfolio of healthcare real estate, with an emphasis on providing senior housing to serve a growing elderly population in the United States. Additional information about the Company can be found on its website at nhpreit.com.

Investor & Media Contact

Email: [email protected]

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain “forward-looking” statements as defined in the Private Securities Litigation Reform
Act of 1995. Forward-looking statements generally can be identified by the use of terminology such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” “should,” “predict,” “project,” “potential,” “continue” or the negatives of these terms or variations of them or similar expressions. Risks and uncertainties, the occurrence of which could adversely affect the Company’s business and cause actual results to differ materially from those expressed or implied in the forward-looking statements, include, but are not limited to, the following: changes in economic cycles generally and in the real estate and healthcare markets specifically; the success of the Company’s growth strategy, including its ability to successfully identify, complete and integrate new acquisitions; the Company’s ability to complete acquisitions or dispositions on the terms and timing the Company expects, or at all; changes to inflation and interest rates; competition in the real estate and healthcare markets; the Company’s ability to retain certain key personnel; legislative and regulatory changes in the healthcare and real estate industries; reductions or changes in reimbursement from third-party payors, including Medicare and Medicaid; discovery of previously undetected environmentally hazardous conditions; the Company’s ability to pay down, refinance, restructure or extend its indebtedness as it becomes due; system failures, cyber incidents or deficiencies in the Company’s cybersecurity systems; the availability of capital on favorable terms, or at all; the Company’s ability to remain qualified as a real estate investment trust for U.S. federal income tax purposes; and other risks and uncertainties described in the section titled Risk Factors of the Company’s most recent Annual Report on Form 10-K and all other filings with the Securities and Exchange Commission. Finally, the Company assumes no obligation to update or revise any forward-looking statements or to update the reasons why actual results could differ from those projected in any forward-looking statements.

RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that new data from the Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026, taking place October 21-25 in Denver, Colorado.

Oral Presentation Details:

Title:	Blood Pressure and Albuminuria Reduction with Lorundrostat in Chronic Kidney Disease Stages 1 to 3 in the Launch-HTN trial
Authors:	Liffert Vogt, MD, PhD, Professor of Nephrology and Renal Transplantation at Amsterdam University Medical Center and University of Amsterdam; Patrick J. Heagerty, PhD, Professor of Biostatistics at University of Washington; Sarbani Bhaduri, MD, MS, Vice President of Clinical Research at Mineralys Therapeutics, Inc.

About Launch-HTN 

The Launch-HTN trial (NCT06153693) was a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial of adults whose blood pressure remained uncontrolled despite being on two to five antihypertensive medications. Participants were assigned to one of three groups: lorundrostat 50 mg once daily; lorundrostat 50 mg once daily with the option to increase to 100 mg at week six based on prespecified criteria; or placebo. The primary endpoint was change from baseline in systolic blood pressure at six weeks versus placebo, measured by automated office blood pressure monitoring.

About Hypertension

Having sustained, elevated blood pressure (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the United States. In 2022, more than 685,000 deaths in the United States included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an estimated annual economic burden of about $219 billion in the United States in 2019.

Less than 50% of hypertensive patients achieve their blood pressure goal with currently available medications. Dysregulated aldosterone levels are a key factor in driving hypertension in approximately 30% of all hypertensive patients.

About Chronic Kidney Disease (CKD)

CKD, which is characterized by the gradual loss of kidney function, is estimated to affect more than 10% of the global population and is one of the leading causes of mortality worldwide. According to the U.S. Centers for Disease Control and Prevention (CDC), more than 1 in 10 (14%) adults aged 18 or older (approximately 37 million people) are estimated to have CKD. Approximately 21% of adults with high blood pressure are estimated to have CKD. The relationship between these conditions is tightly linked: sustained hypertension may contribute to impaired kidney function, and progressive decrease in kidney function may lead to worsening blood pressure. When CKD is present in patients with hypertension, the risk of cardiovascular disease and mortality rises significantly.

Emerging evidence points to dysregulated aldosterone as a key driver of both diseases. Excess aldosterone promotes sodium retention, vascular inflammation and fibrosis, contributing to both uncontrolled blood pressure and kidney injury. Despite the availability of existing therapies, a significant proportion of patients remain uncontrolled or undertreated. Early detection and targeted interventions that address underlying mechanisms, such as aldosterone dysregulation, may offer the potential to slow CKD progression, reduce cardiovascular risk and improve long-term outcomes. Without effective management, CKD can advance to kidney failure, requiring dialysis or transplantation.

About Lorundrostat

Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, has an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in participants with hypertension.

Mineralys has completed six late-stage clinical trials of lorundrostat supporting its efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN and rHTN. The clinical program includes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial, which support the robust, durable and clinically meaningful reductions in systolic blood pressure by lorundrostat. Lorundrostat was well tolerated in both trials with a favorable safety profile.

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Forward-Looking Statements

Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on Mineralys’ current beliefs and expectations and include, but are not limited to, statements regarding the potential therapeutic benefits of lorundrostat. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Mineralys’ business, including, without limitation: any delays in the Food and Drug Administration’s (FDA) review of Mineralys’ accepted new drug application (NDA), including as a result of a government shutdown or reductions in agency funding or personnel; the results of Mineralys’ clinical trials, including the Launch-HTN and Advance-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for regulatory approval of lorundrostat; later developments with the FDA may be inconsistent with the feedback from prior meetings, including whether the proposed pivotal program will support registration of lorundrostat following the FDA’s review of Mineralys’ NDA submission; the risk that future funding under the secured debt facility may not be available on the timeframe Mineralys expects, or at all, including as a result of its failure to meet the conditions required for such funding or failure to comply with the affirmative and negative covenants under the debt facility; Mineralys may not be able to reach agreement on the proposed termination of its license agreement with Tanabe on its expected timeframe, or at all; Mineralys’ future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; Mineralys’ dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs and other trade policies, and the potential for a local and/or global economic recession; Mineralys’ ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; Mineralys’ reliance on its exclusive license with Tanabe to provide Mineralys with intellectual property rights to develop and commercialize lorundrostat; and other risks described in Mineralys’ filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Mineralys undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

Investor Relations

[email protected]

Media Relations

Melyssa Weible
Elixir Health Public Relations
Email: [email protected]

SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company’s common stock, effective as of October 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company’s 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $8.27 per share, equal to the last reported sale price of the Company’s common stock as reported by Nasdaq on October 1, 2026. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.

Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact

Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
[email protected]

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) — ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on September 30, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of 90,775 restricted stock units (“RSUs”) and 32,725 non-qualified stock options (“NSOs”) to three newly hired non-executive employees. The foregoing inducement awards were granted as inducements material to the new employees entering into employment with Imagene in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the Company’s 2025 Equity Inducement Plan and the applicable equity award agreements.

The RSUs for two of the employees vest in equal annual installments over four years, and the RSUs granted to one of the employees vest over four years with 25% of the RSUs vesting after one year and the balance of the RSUs vesting in 12 equal quarterly installments thereafter, in each case subject to the grantee’s continuous service through each vesting date. Each NSO has an exercise price equal to $4.58 per share, the closing price of Imagene’s common stock on September 30, 2026. The NSOs vest over four years, with 25% of the shares vesting after one year and the remaining 75% of the shares vesting in equal monthly installments over the following 36 months, subject to the grantee’s continuous service through each vesting date.

About ImageneBio, Inc.

Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics with differentiated clinical profiles for patients with immunological, autoimmune and inflammatory diseases. The Company’s program, olevaprubart, is a receptor targeting, non-depleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of olevaprubart in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of olevaprubart in patients with moderate-to-severe atopic dermatitis.

Company and Investor Contact

Rebecca Cohen
[email protected]

Media Contact

Jason Braco, PhD
Valence Communications
[email protected]